Literature DB >> 25835982

Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery.

Palanivelu Praveenraj1, Rachel M Gomes2, Saravana Kumar3, Purushothaman Karthikeyan4, Annapoorni Shankar5, Ramakrishnan Parthasarathi6, Palanisamy Senthilnathan7, Subbiah Rajapandian8, Chinnusamy Palanivelu9.   

Abstract

BACKGROUND: Numerous studies worldwide have identified a high prevalence of non-alcoholic fatty liver disease (NAFLD) among morbidly obese subjects. Several predictors have been found to be associated with NAFLD and its histological high-risk components. Similar data from India is lacking. We aimed to determine the prevalence and the predictors of NAFLD and its histological high-risk components in a cohort of Indians with morbid obesity undergoing bariatric surgery. Safety of a routine intraoperative liver biopsy was also assessed.
METHODS: There were 134 morbidly obese patients who underwent bariatric surgery with concomitant liver biopsy. These were assessed for NAFLD and its histological high-risk components. Clinical, biochemical, and histological features were evaluated, and predictors of NAFLD, non-alcoholic steatohepatitis (NASH), fibrosis, and advanced fibrosis were identified.
RESULTS: Mean BMI was 44.66 ± 9.81. Eighty-eight (65.7 %) showed NAFLD. Forty-five (33.6 %) showed NASH and 42 (31.3 %) showed fibrosis both not mutually exclusive. Nineteen (14.1 %) showed advanced fibrosis. Higher alanine aminotransferase (ALT) independently predicted NAFLD and was significantly associated with NASH and fibrosis. Type 2 diabetes mellitus (T2DM) and the metabolic syndrome were significantly associated with fibrosis. Systemic hypertension (HT) independently predicted NASH and fibrosis. There were no intraoperative or postoperative complications related to the liver biopsy.
CONCLUSIONS: NAFLD has a high prevalence among morbidly obese patients. Elevated ALT, HT, T2DM, and the metabolic syndrome are predictors for NAFLD and its high-risk histological components. Routine intraoperative liver biopsy is safe in morbidly obese undergoing bariatric surgery for diagnosing NAFLD.

Entities:  

Keywords:  Bariatric surgery; Cirrhosis; Metabolic syndrome; Morbid obesity; Non-alcoholic liver disease; Non-alcoholic steatohepatitis

Mesh:

Year:  2015        PMID: 25835982     DOI: 10.1007/s11695-015-1655-1

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  36 in total

1.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Authors:  J B Dixon; P S Bhathal; P E O'Brien
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

2.  Prevalence of metabolic syndrome in non-diabetic and non-cirrhotic patients with non-alcoholic steatohepatitis.

Authors:  Deepak N Amarapurkar; Nikhil D Patel
Journal:  Trop Gastroenterol       Date:  2004 Jul-Sep

3.  Clinical spectrum and natural history of non-alcoholic steatohepatitis with normal alanine aminotransferase values.

Authors:  Deepak N Amarapurkar; Nikhil D Patel
Journal:  Trop Gastroenterol       Date:  2004 Jul-Sep

4.  Bariatric surgery worldwide 2003.

Authors:  Henry Buchwald; Stanley E Williams
Journal:  Obes Surg       Date:  2004-10       Impact factor: 4.129

5.  Effect of body mass index on nonalcoholic fatty liver disease in patients undergoing minimally invasive bariatric surgery.

Authors:  Constantine T Frantzides; Mark A Carlson; Ronald E Moore; John G Zografakis; Atul K Madan; Susan Puumala; Ali Keshavarzian
Journal:  J Gastrointest Surg       Date:  2004-11       Impact factor: 3.452

6.  Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease.

Authors:  Jeanne M Clark; Amir R A Alkhuraishi; Steven F Solga; Patricia Alli; Anna Mae Diehl; Thomas H Magnuson
Journal:  Obes Res       Date:  2005-07

7.  Metabolic/bariatric surgery worldwide 2011.

Authors:  Henry Buchwald; Danette M Oien
Journal:  Obes Surg       Date:  2013-04       Impact factor: 4.129

8.  Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease.

Authors:  S A Harrison; D Oliver; H L Arnold; S Gogia; B A Neuschwander-Tetri
Journal:  Gut       Date:  2008-04-04       Impact factor: 23.059

9.  Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome.

Authors:  V Mohan; S Farooq; M Deepa; R Ravikumar; C S Pitchumoni
Journal:  Diabetes Res Clin Pract       Date:  2009-01-24       Impact factor: 5.602

10.  Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic fatty liver disease.

Authors:  Motoi Hashiba; Masafumi Ono; Hideyuki Hyogo; Yukio Ikeda; Kosei Masuda; Reiko Yoshioka; Yoichi Ishikawa; Yuri Nagata; Kensuke Munekage; Tsunehiro Ochi; Akira Hirose; Yasuko Nozaki-Fujimura; Shuhei Noguchi; Nobuto Okamoto; Kazuaki Chayama; Narufumi Suganuma; Toshiji Saibara
Journal:  PLoS One       Date:  2013-11-06       Impact factor: 3.240

View more
  13 in total

1.  Prevalence of nonalcoholic steatohepatitis in Japanese patients with morbid obesity undergoing bariatric surgery.

Authors:  Yosuke Seki; Satoru Kakizaki; Norio Horiguchi; Hiroaki Hashizume; Hiroki Tojima; Yuichi Yamazaki; Ken Sato; Motoyasu Kusano; Masanobu Yamada; Kazunori Kasama
Journal:  J Gastroenterol       Date:  2015-08-28       Impact factor: 7.527

Review 2.  Monitoring of Liver Function Tests after Roux-en-Y Gastric Bypass: An Examination of Evidence Base.

Authors:  Kamal K Mahawar; Chetan Parmar; Yitka Graham; Nimantha De Alwis; William R J Carr; Neil Jennings; Peter K Small
Journal:  Obes Surg       Date:  2016-10       Impact factor: 4.129

3.  Safety and Utility of Liver Biopsy During Bariatric Surgery in the New Zealand Setting.

Authors:  Hannah Collins; Grant Beban; John Windsor; Rishi Ram; David Orr; Nicholas Evennett; Benjamin Loveday
Journal:  Obes Surg       Date:  2020-01       Impact factor: 4.129

Review 4.  Routine Liver Biopsy During Bariatric Surgery: an Analysis of Evidence Base.

Authors:  Kamal K Mahawar; Chetan Parmar; Yitka Graham; Ayman Abouleid; William R J Carr; Neil Jennings; Norbert Schroeder; Peter K Small
Journal:  Obes Surg       Date:  2016-01       Impact factor: 4.129

5.  Roux-en-Y Gastric Bypass Is Associated With Increased Hazard for De Novo Alcohol-related Complications and Liver Disease.

Authors:  Hannah P Kim; Yue Jiang; Timothy M Farrell; Christine M Peat; Paul H Hayashi; Alfred Sidney Barritt
Journal:  J Clin Gastroenterol       Date:  2022-02-01       Impact factor: 3.174

6.  Changes in alanine aminotransferase in adults with severe and complicated obesity during a milk-based meal replacement programme.

Authors:  Razk Abdalgwad; Mohammed Faraz Rafey; Conor Murphy; Iulia Ioana; Paula Mary O'Shea; Eoin Slattery; Colin Davenport; Derek Timothy O'Keeffe; Francis Martin Finucane
Journal:  Nutr Metab (Lond)       Date:  2020-10-16       Impact factor: 4.169

7.  Non-Alcoholic Steatohepatitis (NASH): Risk Factors in Morbidly Obese Patients.

Authors:  Alexandre Losekann; Antonio C Weston; Angelo A de Mattos; Cristiane V Tovo; Luis A de Carli; Marilia B Espindola; Sergio R Pioner; Gabriela P Coral
Journal:  Int J Mol Sci       Date:  2015-10-23       Impact factor: 5.923

8.  Predictors for advanced fibrosis in morbidly obese non-alcoholic fatty liver patients.

Authors:  Shira Zelber-Sagi; Dafna Shoham; Isabel Zvibel; Subhi Abu-Abeid; Oren Shibolet; Sigal Fishman
Journal:  World J Hepatol       Date:  2017-01-18

Review 9.  Non-alcoholic Fatty Liver Disease in South Asians: A Review of the Literature.

Authors:  Sital Singh; Gabriela N Kuftinec; Souvik Sarkar
Journal:  J Clin Transl Hepatol       Date:  2017-02-07

Review 10.  Role of microRNAs in alcohol-induced liver disorders and non-alcoholic fatty liver disease.

Authors:  Jorge-Luis Torres; Ignacio Novo-Veleiro; Laura Manzanedo; Lucía Alvela-Suárez; Ronald Macías; Francisco-Javier Laso; Miguel Marcos
Journal:  World J Gastroenterol       Date:  2018-09-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.